Absence of Activating Mutations of the Genes Encoding theα -Subunits of G11 and Gq in Thyroid Neoplasia1

Activating mutations of the TSH receptor and α-subunit of Gs (Gαs) that increase adenylyl cyclase activity have been identified in a subset of hyperfunctioning benign thyroid follicular adenomas and, less commonly, in hypofunctioning adenomas and carcinomas. In addition, some thyroid tumors exhibit...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 83; no. 2; pp. 554 - 559
Main Authors Ringel, Matthew D, Saji, Motoyasu, Schwindinger, William F, Segev, Dorry, Zeiger, Martha A, Levine, Michael A
Format Journal Article
LanguageEnglish
Published Endocrine Society 01.02.1998
Online AccessGet full text

Cover

Loading…
More Information
Summary:Activating mutations of the TSH receptor and α-subunit of Gs (Gαs) that increase adenylyl cyclase activity have been identified in a subset of hyperfunctioning benign thyroid follicular adenomas and, less commonly, in hypofunctioning adenomas and carcinomas. In addition, some thyroid tumors exhibit inappropriate activation of phospholipase C (PLC), a signaling pathway that has been implicated in the growth and dedifferentiation of thyroid cells. We therefore hypothesized that some thyroid tumors might be caused by somatic mutations in the genes encoding the α-chain of Gq or G11 that result in constitutive activation of the PLC pathway. We amplified regions of theα q and α11 genes that encode amino acids, Q209 and R183, and we screened the DNA for mutations by sequence analysis and denaturing gradient gel electrophoresis. No mutations were identified after analysis of DNA from 38 thyroid tumors and 2 poorly differentiated thyroid carcinoma cell lines, including: 13 follicular adenomas, 10 follicular carcinomas, 5 papillary carcinomas, and 10 hyperplastic nodules from multinodular goiters. We conclude that activating mutations of αq and α11 are absent or rare in hypofunctioning thyroid neoplasms and that other mechanisms must explain the elevated PLC activity reported in thyroid carcinoma.
ISSN:0021-972X
1945-7197
DOI:10.1210/jcem.83.2.4536